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Phloridzin, an antidiabetic and antineoplastic agent usually found in fruit trees, is a
dihydrochalcone constituent that has a clinical/pharmaceutical significance as a sodiumglucose linked transport 2 (SGLT2) inhibitor. Phloridzin never experienced widespread
clinical usage in the pharmaceutical market due to its side effects and poor bioavailability
when compared to other antidiabetic therapeutics. The poor bioavailability is primarily
attributed to the degradation of the glycosidic bond of the phloridzin, resulting in the
formation of phloretin, the aglycone of phloridzin and glucose. While phloretin displays
a reduced capacity of SGLT2 inhibition, this nutraceutical shows enhanced antineoplastic
activity in comparison to phloridzin. Gold nanoparticles (AuNPs) have been explored in
improving the bioavailability of many drugs and therefore we opt for gold nanoparticle
mediated delivery of phloridzin and phloretin and exploration of their anticancer
mechanism. In this study, we have synthesized phloridzin and phloretin conjugated gold
nanoparticles (Phl-AuNP and Pht-AuNP) in a single-step, rapid, biofriendly processes.
The synthesized AuNPs morphology and elemental composition was characterized via
transmission electron microscopy, UV-Vis spectroscopy, scanning electron microscopyenergy dispersive x-ray spectroscopy, and thermogravimetric analysis. Assessment of the
antineoplastic potency of the dihydrochalcone-conjugated AuNPs against cancerous cell
lines was accomplished through monitoring via flow cytometry. We posit that the
functionalization of these chalcones onto the gold nanoparticles’ surface has improved the
pharmacokinetic profile of phloridzin and phloretin.
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1. INTRODUCTION
As of 2016, approximately 1,685,210 individuals in the United States were
diagnosed with some form of cancer1. This rate has been steadily increasing over the past
few decades, which has led to a frantic search for effective cancer treatments. As of 2014,
1,830 drug treatments have been identified and developed2. This seemingly large value is
inadequate and minuscule in comparison to the number of diagnosed cancer cases.
Additionally, most of these treatments are derivatives of chemotherapy, which may induce
significant side effects. The need for more effective treatments that can be used in
combination with some less malignant treatments is of paramount importance to the
medical community.
Dihydrochalcones have been established as potent compounds for a vast array of
pharmaceutical applications such as antidiabetic, antifungal, anti-inflammatory,
antimalarial, antibacterial and antineoplastic medications3–7. A dihydrochalcone pair of
particular interest in this study are phloridzin (1-[2,4-dihydroxy-6-[(2S,3R,4R,5S,6R)3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-phenyl]-3-(4hydroxyphenyl)propan-1-one) and its aglycone, phloretin (3-(4-Hydroxyphenyl)-1(2,4,6-trihydroxyphenyl)-1-propanone).

Phloridzin

was

initially

isolated

for

pharmaceutical usage as the first sodium-glucose linked transporter 2 (SGLT2) inhibitor
in 18388,9. The mechanism of action for phloridzin allowed for the inhibition of glucose
absorption through the SGLT2 due to a binding affinity for SGLT2 that was 3000 times
greater than that of glucose9–11. Given this mechanism, phloridzin was suggested as an
appropriate treatment for hyperglycemia; however, phloridzin never achieved widespread
1

usage due to its poor selectivity and oral bioavailability in comparison to other drug
options. The phloridzin’s poor oral bioavailability is primarily attributed to the presence
of lactase-phloridzin hydrolase in the microvillar membrane of the small intestine12. This
enzyme, intended for the hydrolysis of lactose, hydrolyses the β-glycosidic bond of
phloridzin, resulting in the formation of phloretin and glucose. Phloretin demonstrates
more modest antidiabetic activity, in comparison to phloridzin, due to its mechanism of
action, which focuses on glucose transporter (GLUT) inhibition13. Since phloretin’s
mechanism is much less specific than that of phloridzin, it is ultimately less effective for
the

treatment

of

hyperglycemia.

Through

comprehensive

pharmaceutical

experimentation, it was determined that in addition to potential pharmaceutical application
of phloridzin and phloretin as an antidiabetic agent, these nutraceuticals demonstrated a
significant effect as antineoplastic, antipyretic, and antimalarial agents 9,11,14,15. Of
particular interest is the potential applications of phloridzin and phloretin as antineoplastic
agents. The efficacy of phloridzin and phloretin has been previously examined; it was
determined that both compounds demonstrate a statistically significant antineoplastic
action, where phloretin is more potent than phloridzin5,6,16,17. In order to properly exploit
this activity to its greatest potential, a drug delivery system must be integrated with these
drugs to side-step any inherent bioavailability and selectivity issues.
Nanoscale materials bring a plethora of new possibilities to medicinal chemistry.
Gold nanoparticles (AuNPs) have proven to be particularly useful in medicinal chemistry
due to their chemical stability, ease of surface functionalization, and relative safety, and
have been used for several years for cancer drug delivery and bioimaging18–21. Clinically2

approved, nano-conjugated doxorubicin has demonstrated an enhanced drug
accumulation and retention in multidrug resistant MCF-7/ADR cancer cells22–26. Provided
with the highly hydroxylated structure of both phloridzin and phloretin, conjugation via
hydroxyl group oxidation as an ester linkage to the AuNP structure is possible (Figure 1).
These studies, among others, provide credible evidence that the conjugation of phloridzin
and phloretin to AuNPs have the potential for augmented antineoplastic activity23,26,27.
The successful conversion of an antiquated antidiabetic treatment (phloridzin) and its
biodegraded precursor (phloretin) to a successful antineoplastic treatment would
invigorate and revitalize such efforts, possibly leading to a new wave of effective, costeffective antineoplastic treatments.

Figure 1. Chemical structures of the two dihydrochalcones. (a) phloretin molecular
weight: 274.26 g mol-1, (b) phloridzin molecular weight: 342.30 g mol-1
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2. MATERIALS AND METHODS
2.1. Materials

Dulbecco’s modified Eagle medium
Fetal bovive serum

Catalog
Number
11965-092
10437-028

Formvar 15/95 resin, powder

63450-15-7

Gold(III) chloride trihydrate

520918-5G

Phloretin

P7912-250MG Sigma-Aldrich

Phloridzin dihydrate
Potassium gold(III) chloride
Potassium phosphate, dibasic
(K2HPO4)
Potassium phosphate, monobasic
(KH2PO4)
Potassium sulphate
Sodium chloride

274313-5G
450235-1G

Sigma-Aldrich
Sigma Aldrich

PX1570-1

EMD Chemicals

PX1565-5

EMD Chemicals

PX1595-1
3624-05
W3026001KG

EMD Chemicals
J.T. Baker

SX0718-1

EMD Chemicals

1635632
15400054

Life Technologies
Life Technologies

Chemicals

Sodium citrate dihydrate
Sodium phosphate, dibasic, 12Hydrate
SYTOX AADvanved Dead Cell Stain
Trypsin-EDTA

Vendor
Life Technologies
Life Technologies
Electron Microscopy
Sciences
Sigma Aldrich

Sigma Aldrich

Table 1. Represents list of all the chemicals used for the research project with catalog
number and vendor details respectively.
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2.2. Supplies
Catalog
Number

Supply material
24-Well Flat Bottom, Non-Treated, Sterile,
Polystyrene, Microtiter Plates
Disposable Pasteur Pipets, Glass, Plugged
Falcon Tubes – 15 mL
Falcon Tubes – 50 mL
Glass Culture tubes
Microcentrifuge Tubes – 1.5 mL
Micropipette Tips (1-1000 µL)
Micropipette Tips (1-20 µL)
Micropipette Tips (1-200 µL)
Nalgene™ Oakridge High speed PPCO
centrifuge tubes
Sterile Polystyrene Petri Dish
(100 mm x 15mm)
TEM grids
(400 square mesh, Oval Hole)

Vendor

25381-056

Costar

14672-412
89039-666
89004-364
14-961-27
87003-294
83007-382
53509-070
53503-606

VWR
VWR
VWR
Fisher brand
VWR
VWR
VWR
VWR

3119-0030

Thermo Scientific

875713

Fisher Scientific

G400-Cu

Electron Microscopy
Sciences

Table 2. Represents list of supply material used with catalog number and vendor details
respectively.
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2.3. Equipment
Equipment
Autoclave Machine, GETINGE
Eppendorf Centrifuge
Excella E25 Incubator Shaker
-80 °C Freezer, Thermo scientific
Hitachi U-3900 Spectrophotometer
JEOL JEM-1400 Plus Electron Microscope
JEOL JSM-5400 LV Scanning Microscope
Thermo scientific Bath Circulator (Haake A25,
Haake SC150)
LABONCO Biological Safety Cabinet, Logic,
Class II, Type A2
LABONCO Centrivap Cold Trap Lyophlizer
METTLER TOLEDO New Classic MF
Balance (Model: ML 54/03)
MISONIX ultrasonic Liquid Processor XL2000 Probe Sonicator (Model: CML-4)
NANOpure infinity, Ultrapure water system,
Barnstead water machine
Refrigerator
SPECTRONIC 20D+ Thermo Spectronic
Sorval RC-5B/5C Plus centrifuge
TA Thermogravimetric Analysis, Q5000
VWR Incubator
Zetasizer Nano S (Malvern Instruments Ltd.)

Application
Sterilize solutions and supplies
Concentrate gold nanoparticles
(Small scale)
Bacterial and nanoparticle
incubation
Store bacterial stock culture
Optical absorption of nanoparticle
solution
Morphological characterization of
kanamycin gold nanoparticles
Elemental composition of
nanoparticles
Temperature dependent synthesis of
nanoparticles
Working with bacteria
(aseptic conditions)
Freeze-drying of gold nanoparticles
Weighing of raw materials,
nanoparticles etc.
Break the aggregation of
nanoparticles
Nano pure water (17.8-18.3 mΩ-cm)
Storing the solutions and reagents
Determine optical density of bacteria
Concentrate gold nanoparticles
(Large scale synthesis)
Organic percent determination on
gold nanoparticles
Growth of bacteria on agar plates
Particle size distribution

Table 3. Represents list of equipments used, their make, and uses respectively.
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2.4. Preparation of reagents
2.4.1. Cleaning protocol
All the glassware/apparatus/containers were thoroughly rinsed and washed with soap
water followed by tap water and nanopure water and allowed to air dry. Furthermore, the
apparatus were subjected to dry heat sterilization before use.
2.4.2. Preparation of sterile nanopure water (pH 7.2 ± 0.2)
500 mL of nanopure water was collected in a sterile 1000 mL glass bottle. The cap
was screwed loosely and the nanopure water was sterilized by moist heat sterilization
using an autoclave at 141 °C for 75 minutes.
2.4.3. Preparation of phloretin stock solution: (0.365 M, 300 µL)
30 mg of phloretin was weighed out using a microbalance and transferred to a
prepared 1.5 mL microcentrifuge tube. 300 µL of 100% ethanol was then added to the
microcentrifuge tube. The tube was then thoroughly vortexed until the resultant solution
was clear to ensure adequate dissolution of the phloretin in the ethanol. The phloretin
stock is then divided in 30 µL aliquots in 10-50 mL falcon tubes with 30 mL of autoclaved
nanopure water.
2.4.4. Preparation of phloridzin stock solution: (0.932 mM, 30 mL)
13.5 mg of phloridzin dihydrate was weighed out using a microbalance and
transferred to a prepared 50 mL falcon tube. 30 mL of autoclaved nanopure water was
added to the falcon tube.

7

2.4.5. Preparation of potassium gold (III) chloride stock solution (KAuCl4) (0.79
mM, 5.0 mL)
250 mg of gold salt was weighed and transferred to 15 mL Falcon tube. 5 mL of
sterile nanopure water was added to it. The mixture was vortexed to dissolve the solute
until clear, homogenous yellow solution was obtained. The tube was further stored at 2-8
°C for future use.
2.4.6

Preparation of 1 mM chloroauric acid stock solution
A chloroauric acid solution was prepared by weighing out 101.94 mg on a

microbalance. This was then added to a 500 mL reagent bottle, to which 300 mL of
autoclaved nanopure water was added. A stir bar was inserted in the bottle and the
solution was allowed to be mixed until the solution reached a homogenized pale yellow
color.
2.4.7

Preparation of 1% sodium citrate dihydrate stock solution
1.000 g of sodium citrate dihydrate was weighed out on a microbalance and

added it to a 250 mL bottle. To the reagent bottle, 100 mL of autoclave nanopure water
was added along with a stir bar. The solution was mixed until particles were not visible.
2.4.8. Preparation of 10X phosphate buffer saline (PBS) (1L, pH 7.2 ± 0.2)
Following the cleaning protocol, 5.519 g sodium dihydrogen phosphate, 42.89 g
disodium hydrogen phosphate and 87.66 g sodium chloride were weighed and transferred
to 2 L Erlenmeyer flask. Approximately 800 mL of autoclaved nanopure water was added
and the solutes were mixed to dissolve. The volume was made up to 1000 mL in a
graduated measuring cylinder using autoclaved nanopure water. The pH of solution was
8

adjusted to pH 7.2 using calibrated pH meter. The 500 mL of solution was transferred to
two reagent bottles, screw capped loosely and subjected to moist heat sterilization. After
sterilization, the bottles were labeled, screw capped tightly and stored at room temperature
until further use.
2.4.9. Preparation of 1X phosphate buffer saline (PBS) (0.5L, pH 7.2 ± 0.2)
Following the cleaning protocol, 50 mL of 10X PBS was diluted to 500 mL using
autoclaved nanopure water in a graduated cylinder. The pH of solution was adjusted to
pH 7.2 using calibrated pH meter. This solution was then transferred to 1 L reagent bottle,
screw capped loosely and subjected to moist heat sterilization. After sterilization, the
bottles were labeled, screw capped tightly and stored at room temperature until further
use.
2.4.10. Preparation of 1 % formvar solution
A 1 % solution of formvar was prepared by dissolving 1 gram polyvinyl formvar
desiccated resin powder in 100 mL ethylene dichloride solvent. The formvar mixture was
mixed overnight in order to completely dissolve resin in solvent.
2.4.11. Preparation of TEM grids
The 400 square mesh, copper grids were obtained and washed in 1 M HCl solution
in order to remove any dust particles followed by air-drying. The grids were further
washed in water and air-dried. A final wash with acetone followed by air-drying was done
for copper grids. The burette apparatus was set up and formvar coating solution was added
into burette. A clean glass slide was dipped into the burette holding formvar solution and
9

kept in contact for approximately 20 seconds. The glass slide was removed using tweezer
and air-dried. A surgical grade blade was used to scrap the edges of the glass slide. The
film coating was then further removed from glass slide by immersing it into a glass jar
completely filled with distilled water. The formvar film so obtained was deposited onto
light side of washed copper grids by holding copper grids inversely (light side facing
downwards) and placing it onto formvar film at surface of water. Parafilm was used to
obtain formvar film containing copper grids. The copper grids (with formvar film on top)
were then removed from parafilm using sharp tweezer and kept separately in a petri plate
containing a filter paper.

2.5. Experimental Methods
2.5.1. Synthesis of Phloretin gold nanoparticles (Pht-AuNPs)
Phloretin has a unique solubility issue, as such it is quite soluble in aqueous media
at extreme pressure or it is soluble in the presence of some organic media. To remedy this
issue ethanol was used in the preparation of the phloretin stock to ensure solubility. To
synthesize the Pht-AuNPs, a primary reaction mixture was prepared of 0.365 M phloretin
in 100% ethanol. A secondary reaction mixture of autoclaved deionized water (pH: 7.2 ±
0.2) was preheated in a Thermo Scientific water bath at 80 °C for 20 minutes. Once
adequate heating of the secondary mixture was achieved, an aliquot of the primary
reaction mixture (phloretin in ethanol) was added to result in a 1.22 mM phloretin solution.
This reagent mixture was removed from the water bath after the addition of the ligand, at
which point an aliquot of 0.132 M KAuCl4 was added to the solution to a final
concentration of 0.353 mM KAuCl4. After mixing, a visible colorimetric shift from
10

colorless to dark red was observed, indicating the formation of Pht-AuNPs. The reaction
mixture was subsequently subjected to at least seven cycles of washing and centrifugation
in the small-scale centrifuge (14,000 rpm for 2 hour) with autoclaved nanopure water to
remove any unreacted reagents.
2.5.2

Synthesis of Phloridzin Gold Nanoparticles (Phl-AuNP)
To synthesize the Phl-AuNPs, a primary reaction mixture was prepared of 0.953

mM phloridzin in autoclaved deionized water (pH: 7.2 ± 0.2). This reagent mixture was
preheated in a Thermo Scientific water bath at 90 °C for 10 minutes. Once adequate
heating of the reagent mixture was achieved, an aliquot of 0.132 M KAuCl4 was added to
the solution to a final concentration of 1.50 mM KAuCl4. This reagent mixture was
removed from the water bath after the addition of the KAuCl4. After mixing, a visible
colorimetric shift from colorless to purple was observed, indicating the formation of PhlAuNPs. The reaction mixture was transferred to Oakridge tubes and subsequently
subjected to at least ten cycles of washing and centrifugation in the large-scale centrifuge
(14,000 rpm for 20 minutes) with autoclaved deionized water to remove any unreacted
reagents.
2.5.3

Synthesis of Citrate Gold Nanoparticles
The Turkevich method was employed to synthesize the citrate conjugated gold

nanoparticles28. 200 mL of the 1 mM aurochloric acid stock was preheated to 100 °C at
which point 20 mL of the 1% stock solution of sodium citrate dihydrate was added was
with vigous stirring via a stir bar29. A colorimetric shift from colorless to dark red was
observed within 10 minutes, indicative of the formation of Citrate-AuNPs. The reaction
11

mixture was subsequently removed from the heating source and allowed to cool to 25 °C
before the solution was titrated to a pH of 7.2 ± 0.2. Unbound reactants were removed
by aliquoting the solution into 15 mL falcon tubes and washing with autoclaved
nanopure water and centrifugating (12,000 rpm for 20 minutes) five times.
2.5.4. Lyophilization of Pht-AuNP and Phl-AuNP
There are several advantages in lyophilizing the AuNP samples. The primary
advantage is that lyophilization allows for accurate quantitative determination of the yield
production, a figure that is necessary for future analysis of antineoplastic activity.
Additionally this process allows the product to be stored for a greater duration of time
without product degradation. For lyophilization, Pht-AuNP, Phl-AuNP, and citrate AuNP
were synthesized, washed, centrifuged, and concentrated to the final volumes in multiples
of 2 mL. The LABONCO Centrivap Cold Trap Lyophlizer was switched on 2 hours prior
to freeze-drying to attain - 30 °C. 2 mL aliquots of AuNPs suspensions were then
transferred to stainless steel cups, frozen in liquid nitrogen, and covered with miracloth,
which allows loss of moisture but is not permeable for loss of AuNP. The cups were then
readily transferred to the lyophilization chamber (previously cooled and maintained at 30 °C). The chamber was closed and vacuum was switched on. The samples were kept
overnight at -30 °C. The temperature was gradually increased the following day by 5 °C
at 1-hour intervals between -30 °C and -5 °C, 2 hour intervals between -5 °C and 5 °C and
1 hour intervals between 5 °C and 30 °C. At 30 °C, the lyophilizer vented, switched off,
and the dried Pht-AuNP, Phl-AuNP, and citrate AuNP were collected, weighed accurately
and stored in a glass vial at room temperature for further analysis.
12

2.5.5. Characterization of Pht-AuNP and Phl-AuNP
Determination of the characteristic size, shape, and composition of the AuNP was
necessary for accurate comparison of the antineoplastic activity. Various electron
microscopic and spectroscopic techniques were used to confirm the presence of
dihydrochalcones phloretin and phloridzin on AuNPs surfaces. Since citrate AuNP are
being used as the control, the conformation of the characteristics to the importance is of
the utmost importance.
UV-Vis spectroscopy (UV-Vis)
Gold nanoparticles possess a characteristic optical property, known as surface
plasmon resonance (SPR).30 This SPR band is observed in visible range of light and is
dependent on the size, shape, and chemical environment in which nanoparticles are
present. Hence, UV-Vis spectroscopy was used as a qualitative, analytical spectrometric
technique to confirm the formation of each AuNP. A dilute suspension of each AuNP was
probe sonicated for 15 seconds at 15% amplitude. UV-Vis absorption spectrum of
resulting suspension was recorded in the wavelength range of 400-700 nm using a Hitachi
U-3900 spectrophotometer at a resolution of 0.5 nm and scanning speed of 150 nm/min
while maintaining slit width at set value of 5 nm and path length 10 mm.
Dynamic light scattering (DLS)
DLS is a rapid and accurate technique used to characterize nanoparticles
suspended in liquid medium.31 Diameter and average particle size distribution of
synthesized Pht-AuNP, Phl-AuNP, and Citrate-AuNP were determined using a Zetasizer
Nano S (Malvern Instruments Ltd.). For this analysis sample preparation, 1 mL of 2 mg
13

mL-1 AuNPs suspensions was prepared and probe sonicated. The size was reported as an
average distribution for over 40 runs for each respective sample. The data obtained was
plotted and average particle size distribution along with polydispersity was determined.
Transmission electron microscopy (TEM)
To characterize the morphological properties of the AuNP, such as size and shape,
the samples were examined through transmission electron microscopy (TEM) using a
JEOL JEM 1400Plus electron microscope operating at a 110 kV accelerating voltage. The
TEM possesses high image resolution at nanometer range.32 The TEM operate on the
principle of the interaction of an electron beam with a thin specimen sample. The
transmitted electrons produce a negative image of the sample on a phosphor screen, from
which the size and shape of nanoparticles could be determined. Sample preparation for
TEM characterization involved the placement of 10 µL of each sample suspension on
formvar-coated, 400-mesh copper grids, which were allowed to air-dry for 1 hour. Images
of the samples were acquired through the built-in AMT XR-81M-B camera, which were
subsequently processed via the Capture Engine Software AMT Version 602.600.52.
Scanning electron microscopy-energy dispersive X-Ray spectroscopy (SEM-EDS)
Surface morphology and presence of dihydrochalcone ligands on the surface of
the AuNPs was examined via the surface elemental analysis using a JEOL-JSM-6510 LV
scanning electron microscope (SEM) via energy dispersive X-Ray spectroscopy (EDS)
with IXRF system. For analysis, 50 μL of 1 mg mL-1 sonicated samples of Phl-AuNP and
Pht-AuNP suspensions pipetted on a cleaned silicon wafer. The silicon chips were then
spin coated and dried under vacuum at 80 °C for 2 hours. SEM images of substrates were
14

obtained at 20 kV accelerating voltage and 25kX magnification followed by surface
elemental analysis using energy dispersive spectroscopy (EDS).
Thermogravimetric analysis (TGA)
Thermal analysis is a quantitative method used to determine the amount of organic
ligand conjugated on AuNPs surface.33 Approximately 5 mg of lyophilized AuNPs and
pure phloridzin and phloretin powder was heated individually in a platinum pan supported
by a highly precise microbalance. The pan was introduced into furnace chamber of the
Q5000 TGA and subjected to thermal decomposition from 25 °C to 850 °C. The sample
was heated at rate of 10 °C min -1 with nitrogen (N2) gas being used as the purge gas to a
temperature of 650 °C. At this point the purge gas was switched to oxygen (O2) gas, to
facilitate complete oxidation of the organic ligands present as the temperature increased
from 650 °C to 850 °C at a rate of 10 °C min -1. The weight loss of AuNPs was monitored
as a function of temperature throughout the experiment. The thermal analysis experiment
of Pht-AuNP and Phl-AuNP was repeated three times to confirm the percent weight of
each chalcone ligand on AuNPs’ surface.
Zeta potential
Zeta potential provides a net electrical charge at the interface in colloidal system.34
For nanoparticles suspension, measuring charge of AuNPs is a key parameter for
predicting its stability and potential interactions. The electrostatic charge and stability of
the nanoparticles were determined using a Zetasizer Nano S (Malvern Instruments Ltd.).
1 mg mL-1 AuNP suspensions were prepared by dissolving the samples in deionized water.
The pH of the solution was maintained at a pH of 7.2 ± 0.2 throughout the analysis. The
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analysis was performed at 25 ± 0.3 °C, at a scattering angle of 90°, and the applied voltage
was 100V. Results were reported as the average of 40 measurements for each sample’s ζpotential determination35.
2.5.6 Evaluation of Phl-AuNP and Pht-AuNP antineoplastic activity
The antineoplastic activities of Pht-AuNP and Phl-AuNP were examined against
an established cancerous cell line of cervical cancer cells, HeLa cells. To establish a
baseline the antineoplastic activities of pure phloridzin and phloretin were examined as
well. Citrate-AuNP acted as a control group for determining the effect of AuNP on the
cancerous cell given citrate-AuNP’s established relativistic inert status in the
literature36,37.
Preparation of aseptic culturing conditions
The preparation of the HeLa cultures is dependent upon an aseptic environment;
therefore, a proper procedure for cell culturing must be followed. All preparatory work
must be performed in a LABONCO Biological Safety Cabinet, which must have the hood
sash maintained at the proper position to maintain laminar airflow. Concerning the items
that will be used in the hood they should all be autoclaved, this includes but not limited
to: pipette tip, glass Pasteur pipettes, and 70% ethanol. The 70% ethanol will be used to
sterilize all surface areas and every item that will be entering the culturing area. Finally,
one must ensure that media, supplements, and reagents are sterile to prevent the growth
of any microbial agents in the cell cultures.
Preparation of HeLa cell cultures
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Preparation of the HeLa cell culture was split from the established HeLa cell
culture strain in the Thompson Lab at the Multi-disciplinary Cancer Research Facility in
the Bindley Bioscience Center at Purdue University. To accomplish this a culture media
was created by adding 450 mL of DMEM with 50 mL of FBS to a sterile reagent bottle
and allowing the solution to reach 25 °C in a warming bath. The trypsin-EDTA and 1X
PBS must also be placed in the warming bath and be allowed to reach 25 °C. To begin
splitting of the culture, the existing cell media in the petri plates in which the HeLa cells
are growing must be aspirated. The HeLa cell must then be washed with 8 mL of 1X PBS,
followed by immediate aspiration of the PBS. 2 mL of trypsin-EDTA was added and the
plate gradually rotated to ensure that entire surface of the plate has been covered before
returning the plate to the incubator for 2 minutes. 8 mL of the culture media was added to
the plate upon removal from the incubator to quench the trypsinization. The 10 mL of cell
was transferred into a 15 mL Falcon tube, before aliquoting 2 mL into the prepared 5-10
cm petri plate. The plates were rocked in a back and forth motion to spread to the cells
evenly before adding 8 mL of culture media to the plate and incubating the plates at 37
°C, in 5% CO2 and 95% relative humidity. The resultant HeLa cells were seeded in 24well plates at cell densities of 75,000 cell/well.
Preparation of doped culture media
To test the antineoplastic activity of the drug conjugate AuNP and the pure form
of the drug, it is necessary to devise a means through which the drug can be delivered to
the cell culture. It was determined that the most efficient means of drug delivery was to
dissolve the drug or drug based AuNP in the culture media and then allow the HeLa cell
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to continue to growing in the media, effectively inoculating them without introducing any
stress into the system. To this end stock solution of Pht-AuNP, Phl-AuNP, citrate-AuNP,
phloretin, and phloridzin were all prepared at concentration of 4mg mL-1, 2 mg mL-1, 1
mg mL-1, 0.5 mg mL-1, and 0.25 mg mL-1. Solvation was assured through mixing and
incubation at 37 °C.
In-vitro antineoplastic assay
The determination of the augmented antineoplastic activity of the gold
nanoparticle conjugated systems of phloridzin and phloretin was examined as a function
of the cell viability of a population of inoculated HeLa cells over a given period. The
control groups for this experiment were those of phloretin, phloridzin, and citrate-AuNP.
This in-vitro assay relied upon the 24-well plates that were seeded after the splitting of the
lab’s primary HeLa cell line. After 24 hours, the culture media was replaced with the
previously prepared serum-free culture media containing increasing concentrations of
AuNPs and pure drugs. The plates were incubated for 1 hour and 4 hours after the
inoculation with the sample culture media. After the respective incubation periods for the
plates, the AuNP and pure drugs were removed via several washes with a phosphate buffer
solution (pH: 7.2 ± 0.2), and fresh DMEM supplemented with 10% fetal bovine serum
was added to each well. After a further incubation period of 36 hours, the media was
aspirated and the cells were washed with a phosphate buffer solution. Following the wash,
the cells underwent trypsinization to remove them from their plates and were then added
to fluorescence-activated cell sorting tubes. To each tube 1.0 µL of Sytox 7AAD dead cell
stain was added and incubated in an ice bath at 0 °C – 4 °C for 15 minutes prior to
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fluorescence-activated cell sorting analysis. Fluorescence channel 4 (FL4) was used for
the 7AAD fluorescence analysis. Cell viability percentage was calculated relative to the
untreated cells, which were considered as 100% viability.

3. RESULTS AND DISCUSSION
3.1. Synthesis and characterization of Pht-AuNP and Phl-AuNP
The synthesis of gold nanoparticles has been traditionally, a multi-step process
that relied upon the use of several chemical reagents, namely reducing agents and capping
agents21,28,29,38,39. In general, the process of AuNP formation begins with the addition of a
reducing agent to a gold salt solution, composed of gold ions (Au3+/Au2+), to yield reduced
neutral gold atoms. These ground state gold atoms demonstrate a propensity to aggregate
in a manner that results in a varied shaped, multi-faceted, polyhedron21,40,41. This nanoaggregate of gold atoms would expand without limit unless a capping agent is introduced
into the system to limit the size, and in certain cases, the spatial dimensions28,29,39,42. In
traditional synthesis, methodologies rely on such multi-step processes to ensure the
formation of consistent and stable nanoparticles. However, such methods require
additional steps for purification due to the production of reagent by-products, which
ultimately result in the process having limited scalability due to its labor and material
intensive nature. The methodologies employed in this synthesis procedure allow for a
single-pot reaction mixture that are conveniently and completely biofriendly, which is
highly desirable given the potential medicinal application of the AuNPs produced43. In
this synthetic methodology employed, the numerous electron rich regions of both of the
chalcones (phloridzin and phloretin) serve as the reducing and, ultimately, the capping
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agent. The optimum concentration of the reagents, gold salt and phloridzin or phloretin,
for AuNP synthesis was determined through assessment of the AuNP synthesis efficiency
of a vast array of differing concentrations. Through these arrays, it was determined that
for the optimum synthesis of phloridzin a reaction mixture of 0.953 mM phloridzin and
1.50 mM KAuCl4 in water produced the optimum yield of Phl-AuNPs. In the synthesis of
Pht-AuNPs, it was determined that in order to achieve adequate solvation of the potential
ligand the phloretin, a 0.365 M phloretin solution in absolute ethanol must be prepared,
prior to addition of phloretin to a 0.353 mM KAuCl4 aqueous media (pH: 7.2 ± 0.2),
yielding a 1.22 mM solution of phloretin. These synthesis strategies resulted in the high
yield of Phl-AuNP and Pht-AuNP, respectively, that had stable, mostly monodispersed,
and uniform morphological characteristics.
Analysis of the morphological characteristics and particle aggregation character of
the Phl-AuNPs and Pht-AuNPs was accomplished through TEM analysis operating at
110kV. TEM micrographs of Phl-AuNPs revealed the nanoparticles to all be spheroid,
with low amounts of aggregation, and a particle core diameter of 15 ± 5 nm (Figure 2.1(a)).
Similar analysis of Pht-AuNP revealed spheroid nanoparticles that exhibited very little
aggregation and a particle core diameter of 8 ± 3 nm (Figure 2.2(a)). The size and
approximate shape was confirmed through analysis of the AuNPs via UV-Vis
spectroscopy by exploiting the principle characteristic of metallic nanoparticles know as
surface plasmon resonance (SPR). SPR is a phenomenon in which the AuNP, when
exposed to an oscillating electromagnetic field in the form of light, experiences an induced
oscillation of the conduction band electrons of the metallic nanoparticle44–46. This
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oscillation of nanoparticle electrons results in a charge separation. The frequency at which
the amplitude of this electron field is at its maximum is defined as the SPR and is
characterized by a strong absorption of the incident light responsible for the
oscillation44,46,47. This characteristic is dependent upon the size of the nanoparticle in
question therefore through the application of spectroscopy the size of the AuNPs and their
rough spatial arrangement can be estimated48,49. The UV-Vis spectroscopic analysis
indicated peak absorptions (λmax) at 536 nm and 542 nm for Pht-AuNPs and Phl-AuNPs
respectively (Figure 2.1(b) and Figure 2.2(b)). Given the presence of ligands on the AuNP
core, it can be inferred that the particles are spheroid and the size is in fact in agreement
with the data collected for TEM analysis44,50. Through the application of DLS analysis, it
was possible to determine the hydrodynamic radii distribution of the AuNPs, which,
unlike the TEM core diameter determination, is a measure of the particle diameter
including the conjugated ligands31. It was determined that the hydrodynamic radii were 8
± 2 nm and 12 ± 2 nm for Pht-AuNPs and Phl-AuNPs respectively (Figure 2.1(c) and
Figure 2.2(c)).
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Figure 2

Figure 2. Illustration of the morphological and size characterization of synthesized PhtAuNPs and Phl-AuNP through TEM, UV-Vis, and DLS analysis. I (a) TEM image
showing formation of well-dispersed spherical Pht-AuNPs with a core size range of 8 ± 3
nm (scale bar= 50 nm). II (a) TEM image showing formation of well-dispersed spherical
Phl-AuNPs with a core size range of 15 ± 5 nm (scale bar= 100 nm). I (b) UV-Vis
spectrogram of Pht-AuNPs showing a SPR event occurring at 536 nm correlating to
spheroid-shaped nanoparticles. II (b) UV-Vis spectrogram of Phl-AuNPs showing a SPR
event occurring at 542 nm correlating to spheroid-shaped nanoparticles. I(c) Pht-AuNP
DLS analysis shows the average hydrodynamic diameter as 8 ± 2 nm. II(c) Phl-AuNP
DLS analysis depicts the average hydrodynamic diameter as 12 ± 2 nm.
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In order to confirm the conjugation of the ligands (phloretin and phloridzin) to the
nanoparticle, it was necessary to perform an elemental composition analysis. This
characterization was achieved through SEM-EDS, an analytical technique that allows for
the presence of carbon and oxygen to be confirmed. In this analysis the presence of both
elements is confirmation of the presence of an organic ligand, specifically the drugs of
interest, as the ligands are the only source of either element in the synthesis of each
AuNPs. Concerning both Pht-AuNP and Phl-AuNP analysis, it was confirmed that an
organic molecule was indeed present, and given the method of sample preparation for both
AuNPs that organic component must correspond to the drug being conjugated to the AuNP
(Figure 3.1(a) and Figure 3.2(a))43. Quantitative analysis of EDS spectrum produced
indicated that gold accounted for 78.66% and 95.01% of the elemental composition of
Pht-AuNPs and Phl-AuNPs respectively, while carbon accounted for 15.27% and 4.27%
of the elemental composition of Pht-AuNP and Phl-AuNP respectively. Additionally, the
oxidation state of the gold in the sample can be determined through EDS analysis
depending on the shift of gold peak on the spectrogram. A position of approximately 2.120
keV corresponds to reduced gold (Au0) whereas peaks of approximately 9.712 keV
corresponds to oxidized gold species (Au2+/Au3+)51,52. The spectrum indicated the strong
presence of gold in the reduced state, a state that is indicative of the presence of gold in a
nanoparticle formation. For a quantitative elemental composition mass analysis,
thermogravimetric analysis (TGA) was employed. Using this method the mass percentage
composition of the organic percentage can be determined from lyophilized, powder
samples ensuring that the only source of organic materials is the proposed ligands. It was
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determined through the analysis that the mass percentage composition of Pht-AuNPs was
16.2% organic whereas Phl-AuNP was 4.0% organic (Figure 3.1(b) and Figure 3.2(b)).
The differing mass percentages between Pht-AuNPs and Phl-AuNPs in both EDS and
TGA can be accounted for due to the size of each respective ligand. Phloretin is the smaller
of the two ligands as it is the aglycone of phloridzin, as such, it is to be expected that more
of the smaller phloretin ligand can be conjugated to each AuNP in comparison to
phloridzin. Zeta potential (ζ) analysis determined the electrokinetic potential of the AuNP
samples, allowing for inference to be made regarding the stability of the AuNP in a
suspension53,54. It was determined that the zeta potential for Pht-AuNPs was -31.7 mV
(Figure 4(a)) whereas the potential for Phl-AuNPs was -38.2 mV (Figure 4(b)). In the case
of both Pht-AuNP and Phl-AuNP their zeta potentials one can conclude that they
demonstrate moderate stability, as the magnitude of the experimentally determined ζ is
greater than 30 mV.
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Figure 3

Figure 3: I (a) Energy dispersive spectroscopy (EDS) spectra of Pht-AuNPs showing
the presence of an elemental peak for carbon (C) and gold (Au) at 0.2keV and 2.1keV
respectively. Figure in the inset shows SEM image of spin coated sample of Pht-AuNPs
on silicon chip obtained at an accelerating voltage of 20 keV with a magnification of
5kX. II (a) Energy dispersive spectroscopy (EDS) spectra of Pht-AuNPs showing the
presence of an elemental peak for carbon (C) and gold (Au) at 0.2keV and 2.1keV
respectively. Figure in the inset shows SEM image of spin coated sample of Pht-AuNPs
on silicon chip obtained at an accelerating voltage of 20 keV with a magnification of
5kX. I (b) A comparison of thermo-gravimetric (TGA) analysis showing loss of organic
material for Pht-AuNP (----) and phloretin (- - -) respectively. The samples were heated
from room temperature to 650 °C at a rate of 10 °C min-1 under nitrogen flow followed
by heating until 850 °C under air. II (b) A comparison of thermo-gravimetric (TGA)
analysis showing loss of organic material for Phl-AuNP (----) and phloridzin (- - -)
respectively. The samples were heated from room temperature to 650 °C at a rate of 10
°C min-1 under nitrogen flow followed by heating until 850 °C under air.
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Figure 4

Figure 4. (a) Surface zeta potential analysis of Pht-AuNP determined to be -31.7mV and
(b) of Phl-AuNP determined to be -38.2 mV. The magnitude of the zeta potential greater
than 30 mV is indicative of a moderately stable AuNP suspension.

26

3.2. Evaluation of Pht-AuNP and Phl-AuNP for antineoplastic activity
The antineoplastic potentials of the synthesized Pht-AuNP and Phl-AuNP were
evaluated via live/dead cell fluorescence staining assays through flow-cytometry. To
perform this analysis, HeLa cells were selected to act as the model cancerous cell line.
Citrate AuNPs were used as a control to evaluate the effect of the AuNP, while pure
phloretin and phloridzin were used as controls to evaluate any augmented antineoplastic
activity resulting from the conjugation of the drugs to the AuNP core. The efficacy of the
samples was determined by the cell viability of the HeLa cells in comparison to noninoculated HeLa cells. It was determined that inoculation times greater than 1 hour yield
no statistically different cell inhibition percentages; therefore, all values represented are
1-hour post inoculation. Additionally, it was discovered that all concentrations of the
samples display increasing cancerous cell cytotoxicity to a concentration of 4 mg/mL.
Above 4 mg/mL, no significant increase in anticancer activity was observed. The flowcytometry assays revealed that the pure forms of the drug ligands, phloretin and
phloridzin, resulted in a HeLa cell viability of 95.000% and 88.125% respectively (Figure
5(a)). The assays that evaluated the synthesize AuNP conjugates, Pht-AuNP and PhlAuNP, displayed a cell viability of 12.750% and 44.625%, respectively (Figure 5(b)). The
efficacy of pure AuNPs was evaluated to determine if the augmented cytotoxicity was due
to a synergistic effect of the conjugation or was purely due to the presence of the AuNPs.
To determine the augmented synergistic potential of AuNPs, citrate-AuNPs of comparable
size to the Pht-AuNP and Phl-AuNP (20 ± 5 nm) were synthesized. The surface zeta
potential of the citrate-AuNPs was determined to be -33.5 mV. It was found, through
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analysis of citrate-AuNP, that cell viability remained at 85.000% indicating the increase
in toxicity was a result of a synergistic activity (Figure 5(c)). These assays demonstrate a
significant increase in the cancerous cell toxicities as a result of the conjugation of the
drugs to AuNPs, as indicated by the 17.45-fold increase in the efficacy of Pht-AuNPs over
pure phloretin, and the 4.49-fold increase in efficacy of Phl-AuNP over pure phloridzin.
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Figure 5

Figure 5. HeLa live/dead cell fluorescence staining analysis via flow-cytometry. (a)
Comparison of the pure drug forms of phloretin and phloridzin to non-inoculated cells.
(b) Comparison of the AuNP functionalized forms of the drugs to non-inoculated cells.
(c) Comparison of the functionalized AuNP to pure AuNP to determine the synergistic
activity of the Pht-AuNP and Phl-AuNP.
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4. CONCLUSION
The results concerning the functionalization of the dihydrochalcones, phloretin
and phloridzin, to AuNP in an effort to augment the existing antineoplastic activity of each
pharmaceutical agent reveal a potential treatment application. The functionalized AuNPs
were synthesized via a single-step method that relied only upon the redox potential of the
conjugate itself and required no toxic chemicals. The synthesized Phl-AuNPs were found
to be in the size range of 15 ± 5 nm, whereas the Pht-AuNP were found to be 8 ± 3 nm,
placing both AuNP conjugated well within the size range necessary for successful
pharmaceutical applications. Significant multi-fold increases in the antineoplastic activity
of both phloretin and phloridzin were observed upon the functionalization of the
pharmaceutical agents to AuNPs in comparison to their pure drug forms. Evaluation of
the antineoplastic of non-functionalized AuNP in conjunction with this data revealed that
the augmented antineoplastic activity was in fact a result of a synergistic effect between
the AuNP and each of the respective drugs. In conclusion, we report a simple, bio-friendly
process using the reducing and capping potential of the dihydrochalcones, phloridzin and
phloretin, to synthesize stable AuNP that have promising futures as potential
antineoplastic agents.
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5. FUTURE STUDIES
Mechanistic Studies of Pht-AuNP and Phl-AuNP Mode of Action
Future studies will focus on the antineoplastic mechanism of action of which
phloretin and phloridzin. Previous studies have suggested that this mechanism is linked to
the glucose-6-phosphate pathway or the inhibiting of DNA topoisomerases therefore that
will be an area of interest55–57. Furthermore, the mechanism of the synergistic effect
between both phloridzin and phloretin and the AuNP resulting in an augmented
antineoplastic effect must be furthered studied. While a rudimentary understanding is
being developed between ligands and AuNP in other applications due to the “electron sink
effect” that phenomenon would seem not to apply here and thus open the possibility for a
wide area of study58.
In vivo interaction of Pht-AuNP and Phl-AuNP in animal model
In order to use a nano-formulation for biological applications, the Pht-AuNP and
Phl-AuNP should be tested for in vivo activity in experimental animal models. This will
be done by studying the physiological changes occurring in animal systems upon acute
and chronic exposure to Pht-AuNP and Phl-AuNP.51 A concentration of the
dihydrochalcone AuNPs will be administered intravenously to the experimental animal
model and animals will be studied for various parameters such as change in body
temperature, body weight and behavior before and after treatment with each AuNP.51 The
blood and urine samples will be collected at specific time intervals and tested for
hematological and urinary analysis. For detailed interaction studies, serum biochemical
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and histo-pathological analysis will also be done.51 All the toxicity analysis will be done
for both AuNPs and will be compared with their respective pure drug forms.

32

6. REFERENCES
(1)
(2)
(3)
(4)

(5)
(6)

(7)

(8)
(9)
(10)

(11)
(12)

(13)
(14)
(15)
(16)

(17)

National Cancer Institute. NIH National Cancer Institute Cancer Statisitics. 2016.
National Cancer Institute. SEER*Rx Interactive Antineoplastic Drugs Database.
2014.
Lesse, W. I. Ueber Diabetes Bei Frauen. Monatsschrift Für Geburtshilfe Gynäkol.
1902, 15 (4), 680–693.
Norton, L.; Instructor; DeFronzo, R. A.; Professor of Medicine and Chief; AbdulGhani, M. A.; Assistant Professor of Medicine, Division of Diabetes, University
of Texas Health Science Center at San Antonio. Sodium–Glucose Co-Transporter
2 Inhibition – A Novel Strategy for Glucose Control in Type 2 Diabetes. Eur.
Endocrinol. 2010, 7 (1), 30.
Nelson, J. A.; Falk, R. E. The Efficacy of Phloridzin and Phloretin on Tumor Cell
Growth. Anticancer Res. 1993, 13 (6A), 2287–2292.
Nelson, J. A.; Falk, R. E. Phloridzin and Phloretin Inhibition of 2-Deoxy-DGlucose Uptake by Tumor Cells in Vitro and in Vivo. Anticancer Res. 1993, 13
(6A), 2293–2299.
Nakamura, Y.; Watanabe, S.; Miyake, N.; Kohno, H.; Osawa, T.
Dihydrochalcones: Evaluation as Novel Radical Scavenging Antioxidants. J.
Agric. Food Chem. 2003, 51 (11), 3309–3312.
Stas, J. S. Ueber das Phloridzin. J. F�r Prakt. Chem. 1839, 17 (1), 273–298.
Ehrenkranz, J. R. L.; Lewis, N. G.; Ronald Kahn, C.; Roth, J. Phlorizin: A
Review. Diabetes Metab. Res. Rev. 2005, 21 (1), 31–38.
Vick, H.; Diedrich, D. F.; Baumann, K. Reevaluation of Renal Tubular Glucose
Transport Inhibition by Phlorizin Analogs. Am. J. Physiol. 1973, 224 (3), 552–
557.
Biegeleisen, H. Phlorizin Analogues and Their Use. US3523937 A, August 11,
1970.
Wüthrich, M.; Sterchi, E. E. Human Lactase-Phlorizin Hydrolase Expressed in
COS-1 Cells Is Proteolytically Processed by the Lysosomal Pathway. FEBS Lett.
1997, 405 (3), 321–327.
Lefevre, P. G. Sugar Transport in the Red Blood Cell: Structure-Activity
Relationships in Substrates and Antagonists. Pharmacol. Rev. 1961, 13, 39–70.
Petersen, C. Analyse Des Phloridzins. Ann. Acad. Sci. Francaise 1835, 15, 178.
de Koninck, L. Observations Sur Les Proprietes Febrifuges de Las Phloridzine.
Bull. Soc. Sci. Medicales 1836, 1, 75–110.
Wang, L.; Li, Z.-W.; Zhang, W.; Xu, R.; Gao, F.; Liu, Y.-F.; Li, Y.-J. Synthesis,
Crystal Structure, and Biological Evaluation of a Series of Phloretin Derivatives.
Molecules 2014, 19 (10), 16447–16457.
Crespy, V.; Aprikian, O.; Morand, C.; Besson, C.; Manach, C.; Demigné, C.;
Rémésy, C. Bioavailability of Phloretin and Phloridzin in Rats. J. Nutr. 2001, 131
(12), 3227–3230.
33

(18) You, J.-O.; Guo, P.; Auguste, D. T. A Drug-Delivery Vehicle Combining the
Targeting and Thermal Ablation of HER2+ Breast-Cancer Cells with Triggered
Drug Release. Angew. Chem. Int. Ed. 2013, 52 (15), 4141–4146.
(19) Zhou, Y.; Kong, Y.; Kundu, S.; Cirillo, J. D.; Liang, H. Antibacterial Activities of
Gold and Silver Nanoparticles against Escherichia Coli and Bacillus CalmetteGuérin. J. Nanobiotechnology 2012, 10 (1), 19.
(20) Seil, J. T.; Webster, T. J. Antimicrobial Applications of Nanotechnology:
Methods and Literature. Int. J. Nanomedicine 2012, 7, 2767–2781.
(21) Shah, M.; Badwaik, V. D.; Dakshinamurthy, R. Biological Applications of Gold
Nanoparticles. J. Nanosci. Nanotechnol. 2014, 14 (1), 344–362.
(22) Zhang, L.; Gu, F.; Chan, J.; Wang, A.; Langer, R.; Farokhzad, O. Nanoparticles in
Medicine: Therapeutic Applications and Developments. Clin. Pharmacol. 38
Ther. 2008, 83 (5), 761–769.
(23) Aryal, S.; Grailer, J. J.; Pilla, S.; Steeber, D. A.; Gong, S. Doxorubicin
Conjugated Gold Nanoparticles as Water-Soluble and pH-Responsive Anticancer
Drug Nanocarriers. J. Mater. Chem. 2009, 19 (42), 7879.
(24) Gu, Y.-J.; Cheng, J.; Man, C. W.-Y.; Wong, W.-T.; Cheng, S. H. GoldDoxorubicin Nanoconjugates for Overcoming Multidrug Resistance.
Nanomedicine Nanotechnol. Biol. Med. 2012, 8 (2), 204–211.
(25) Prabaharan, M.; Grailer, J. J.; Pilla, S.; Steeber, D. A.; Gong, S. Gold
Nanoparticles with a Monolayer of Doxorubicin-Conjugated Amphiphilic Block
Copolymer for Tumor-Targeted Drug Delivery. Biomaterials 2009, 30 (30),
6065–6075.
(26) Wang, F.; Wang, Y.-C.; Dou, S.; Xiong, M.-H.; Sun, T.-M.; Wang, J.
Doxorubicin-Tethered Responsive Gold Nanoparticles Facilitate Intracellular
Drug Delivery for Overcoming Multidrug Resistance in Cancer Cells. ACS Nano
2011, 5 (5), 3679–3692.
(27) Brown, S. D.; Nativo, P.; Smith, J.-A.; Stirling, D.; Edwards, P. R.; Venugopal,
B.; Flint, D. J.; Plumb, J. A.; Graham, D.; Wheate, N. J. Gold Nanoparticles for
the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin.
J. Am. Chem. Soc. 2010, 132 (13), 4678–4684.
(28) Turkevich, J.; Stevenson, P. C.; Hillier, J. A Study of the Nucleation and Growth
Processes in the Synthesis of Colloidal Gold. Discuss. Faraday Soc. 1951, 11, 55.
(29) Kimling, J.; Maier, M.; Okenve, B.; Kotaidis, V.; Ballot, H.; Plech, A. Turkevich
Method for Gold Nanoparticle Synthesis Revisited. J. Phys. Chem. B 2006, 110
(32), 15700–15707.
(30) Hutter, E.; Fendler, J. H. Exploitation of Localized Surface Plasmon Resonance.
Adv. Mater. 2004, 16 (19), 1685–1706.
(31) Khlebtsov, B. N.; Khlebtsov, N. G. On the Measurement of Gold Nanoparticle
Sizes by the Dynamic Light Scattering Method. Colloid J. 2011, 73 (1), 118–127.
(32) S. Pender, D.; M. Vangala, L.; D. Badwaik, V.; Thompson, H.; Paripelly, R.;
Dakshinamurthy, R. A New Class of Gold Nanoantibiotics- Direct Coating of
Ampicillin on Gold Nanoparticles. Pharm. Nanotechnol. 2013, 1 (2), 126–135.
34

(33) Demurtas, M.; Perry, C. C. Facile One-Pot Synthesis of Amoxicillin-Coated Gold
Nanoparticles and Their Antimicrobial Activity. Gold Bull. 2013, 47 (1–2), 103–
107.
(34) Gold Nanoparticles: Weakly Charged Cationic Nanoparticles Induce DNA
Bending and Strand Separation. Adv. Mater. 2012, 24 (31), 4261–4265.
(35) Nanotechnology Characterization Laboratory. Measuring Zeta Potential of
Nanoparticles, NCL Method PCC-2; National Cancer Institute-Frederick:
Frederick, MD, 2009.
(36) Jeerage, K. M.; Oreskovic, T. L.; Curtin, A. E.; Sanders, A. W.; Schwindt, R. K.;
Chiaramonti, A. N. Citrate-Stabilized Gold Nanoparticles as Negative Controls
for Measurements of Neurite Outgrowth. Toxicol. In Vitro 2015, 29 (1), 187–194.
(37) Payne, J. N.; Waghwani, H. K.; Connor, M. G.; Hamilton, W.; Tockstein, S.;
Moolani, H.; Chavda, F.; Badwaik, V.; Lawrenz, M. B.; Dakshinamurthy, R.
Novel Synthesis of Kanamycin Conjugated Gold Nanoparticles with Potent
Antibacterial Activity. Front. Microbiol. 2016, 7.
(38) Brust, M.; Walker, M.; Bethell, D.; Schiffrin, D. J.; Whyman, R. Synthesis of
Thiol-Derivatised Gold Nanoparticles in a Two-Phase Liquid?Liquid System. J.
Chem. Soc. Chem. Commun. 1994, No. 7, 801.
(39) Hutchings, G. J.; Brust, M.; Schmidbaur, H. Gold—an Introductory Perspective.
Chem. Soc. Rev. 2008, 37 (9), 1759.
(40) Handbook of Nanobiomedical Research: Fundamentals, Applications, and Recent
Developments; Torchilin, V. P., Ed.; Frontiers in nanobiomedical research; World
Scientific: [Hackensack,] New Jersey, 2014.
(41) Perala, S. R. K.; Kumar, S. On the Mechanism of Metal Nanoparticle Synthesis in
the Brust–Schiffrin Method. Langmuir 2013, 29 (31), 9863–9873.
(42) Navarro, J. R. G.; Lerouge, F.; Cepraga, C.; Micouin, G.; Favier, A.; Chateau, D.;
Charreyre, M.-T.; Lanoë, P.-H.; Monnereau, C.; Chaput, F.; Marotte, S.;
Leverrier, Y.; Marvel, J.; Kamada, K.; Andraud, C.; Baldeck, P. L.; Parola, S.
Nanocarriers with Ultrahigh Chromophore Loading for Fluorescence Bio-Imaging
and Photodynamic Therapy. Biomaterials 2013, 34 (33), 8344–8351.
(43) Dakshinamurthy, R.; Sahi, S. Monodisperse Gold Nanoparticles and Facile,
Environmentally Favorable Process for Their Manufacture. US8257670 B1,
September 4, 2012.
(44) Huang, X.; El-Sayed, M. A. Gold Nanoparticles: Optical Properties and
Implementations in Cancer Diagnosis and Photothermal Therapy. J. Adv. Res.
2010, 1 (1), 13–28.
(45) Mie, G. Contributions to the Optics of Turbid Media, Particularly of Colloidal
Metal Solutions. Ann. Phys. 1908, 25 (3), 377–445.
(46) Kreibig, U.; Vollmer, M. Optical Properties of Metal Clusters; Toennies, J. P.,
Gonser, U., Osgood, R. M., Panish, M. B., Sakaki, H., Lotsch, H. K. V., Series
Eds.; Springer Series in Materials Science; Springer Berlin Heidelberg: Berlin,
Heidelberg, 1995; Vol. 25.
(47) Papavassiliou, G. C. Optical Properties of Small Inorganic and Organic Metal
Particles. Prog. Solid State Chem. 1979, 12 (3–4), 185–271.
35

(48) Jain, P. K.; Lee, K. S.; El-Sayed, I. H.; El-Sayed, M. A. Calculated Absorption
and Scattering Properties of Gold Nanoparticles of Different Size, Shape, and
Composition: Applications in Biological Imaging and Biomedicine. J. Phys.
Chem. B 2006, 110 (14), 7238–7248.
(49) Huang, X.; Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A. Gold Nanoparticles:
Interesting Optical Properties and Recent Applications in Cancer Diagnostics and
Therapy. Nanomed. 2007, 2 (5), 681–693.
(50) Ali, M. E.; Hashim, U.; Mustafa, S.; Che Man, Y. B.; Islam, K. N. Gold
Nanoparticle Sensor for the Visual Detection of Pork Adulteration in Meatball
Formulation. J. Nanomater. 2012, 2012, 1–7.
(51) Grieken, R. E. van. Handbook of X-Ray Spectrometry; Marcel Dekker: New York,
2002.
(52) Badwaik, V. D.; Bartonojo, J. J.; Evans, J. W.; Sahi, S. V.; Willis, C. B.;
Dakshinamurthy, R. Single-Step Biofriendly Synthesis of Surface Modifiable,
near-Spherical Gold Nanoparticles for Applications in Biological Detection and
Catalysis. Langmuir ACS J. Surf. Colloids 2011, 27 (9), 5549–5554.
(53) Greenwood, R. Review of the Measurement of Zeta Potentials in Concentrated
Aqueous Suspensions Using Electroacoustics. Adv. Colloid Interface Sci. 2003,
106 (1–3), 55–81.
(54) O’Brien, R. W.; Midmore, B. R.; Lamb, A.; Hunter, R. J. Electroacoustic Studies
of Moderately Concentrated Colloidal Suspensions. Faraday Discuss. Chem. Soc.
1990, 90, 301.
(55) Nair, S. V. G.; Ziaullah; Rupasinghe, H. P. V. Fatty Acid Esters of Phloridzin
Induce Apoptosis of Human Liver Cancer Cells through Altered Gene Expression.
PLoS ONE 2014, 9 (9), e107149.
(56) Bissinger, R.; Fischer, S.; Jilani, K.; Lang, F. Stimulation of Erythrocyte Death by
Phloretin. Cell. Physiol. Biochem. 2014, 34 (6), 2256–2265.
(57) Shao, X.; Bai, N.; He, K.; Ho, C.-T.; Yang, C. S.; Sang, S. Apple Polyphenols,
Phloretin and Phloridzin: New Trapping Agents of Reactive Dicarbonyl Species.
Chem. Res. Toxicol. 2008, 21 (10), 2042–2050.
(58) Li, J.; Zhou, H.; Qian, S.; Liu, Z.; Feng, J.; Jin, P.; Liu, X. Plasmonic Gold
Nanoparticles Modified Titania Nanotubes for Antibacterial Application. Appl.
Phys. Lett. 2014, 104 (26), 261110.
(59) In Vivo PK/PD Studies | Nanomedicines Characterization Core Facility.

36

